PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

MAIN INCLUSION CRITERIA Providing informed consent and able to co-operate with the study requirements. Diagnosis of any advanced solid tumour with liver metastases suitable for FOLFOX or FOLFIRI chemotherapy (Part 1a) / Diagnosis of any metastatic CRC with liver metastases suitable for FOLFIRI chemotherapy (Part 1b) . At least two distinct target liver metastases (visible on computed tomography (CT)/magnetic resonance imaging (MRI) and of a suitable size), one being suitable for ultrasound and suitably spaced apart. Eastern Co-operative Oncology performance status of 0 or 1 and with a predicted meaningful survival of at least 6 months. . Suitable laboratory test results to receive chemotherapy. Females who are not pregnant or lactating; males and females willing to follow contraceptive requirements. Able to receive CT/MRI contrast agents. MAIN EXCLUSION CRITERIA Liver metastases suitable for immediate resection (and therefore neoadjuvant therapy unnecessary) or planned to be treated with radio-frequency ablation or other local therapies. Liver radiotherapy in the last 2 months. Use of tyrosine kinase inhibitors or monoclonal antibodies that are known to target angiogenesis receptors and/or their ligands. Persistent, unresolved National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) Version 5.0 Grade 2 or higher drug-related toxicity (except alopecia, erectile dysfunction, hot flashes, decreased libido) following previous treatment. Grade 2 or greater sensory/motor neuropathy. Inadequate recovery from any prior surgical procedure or major surgical procedure in the last 4 weeks Serious/symptomatic active infection, or infection requiring antibiotics in the last 7 days, active cholangitis, disease requiring metal biliary stent(s), HIV infection, bleeding diathesis or other medical or psychiatric condition that might interfere with the patient's participation in the trial or results. Hypersensitivity to any of the components of PS101 (e.g. eggs or egg products). Hypersensitivity to FOLFOX or FOLFIRI, or previously having to discontinue either due to adverse events. Participation in any other clinical trials involving therapeutic agents in the last 4 weeks. History of QT prolongation, clinically significant ventricular tachycardia, ventricular fibrillation, heart block, myocardial infarction within 6 months, congestive heart failure New York Heart Association Class III or IV, unstable angina or any relevant clinical history, signs or symptoms suggestive of clinically significant, uncontrolled cardiovascular or pulmonary disease.